In this episode of MedInsights Unleashed, Wayne Paterson, Vice Chairman and CEO of Anteris Technologies, joins us to discuss one of the fastest evolving areas in structural heart disease — whether the future of valve replacement lies not only in replacing diseased valves, but also in restoring more natural heart flow.
The discussion explores aortic stenosis, the evolution of TAVR, and the emerging science and MRI data surrounding DurAVR THV, including the potential importance of flow dynamics, laminar flow, durability, and long-term valve performance.
We also discuss patient selection, future valve innovation, and how next-generation technologies may move beyond simply treating obstruction toward restoring more natural cardiovascular physiology.
